WO1985004589A1 - Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs - Google Patents

Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs Download PDF

Info

Publication number
WO1985004589A1
WO1985004589A1 PCT/US1985/000596 US8500596W WO8504589A1 WO 1985004589 A1 WO1985004589 A1 WO 1985004589A1 US 8500596 W US8500596 W US 8500596W WO 8504589 A1 WO8504589 A1 WO 8504589A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
steroidal anti
ibuprofen
acid derivative
drug
Prior art date
Application number
PCT/US1985/000596
Other languages
French (fr)
Inventor
Abraham Sunshine
Eugene M. Laska
Carole E. Siegel
Original Assignee
Abraham Sunshine
Laska Eugene M
Siegel Carole E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24395811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1985004589(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abraham Sunshine, Laska Eugene M, Siegel Carole E filed Critical Abraham Sunshine
Priority to AT85901895T priority Critical patent/ATE72989T1/en
Priority to DE8585901895T priority patent/DE3585495D1/en
Publication of WO1985004589A1 publication Critical patent/WO1985004589A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates generally to novel pharmaceutical compositions of matter comprising one or more non-steroidal anti-inflammatory drugs (NSAID) in combination with at least one antihistamine, sympathomimetic drug (nasal decongestant, bronchodilator) cough suppressant and/or expectorant, optionally in combination with suitable pharmaceutically acceptable non-toxic carriers or excipients, and to methods of using said compositions in the treatment, management or mitigation of cough, cold, cold-like and/or flu symptoms and the discomfort, pain, fever and general malaise associated therewith.
  • NSAID non-steroidal anti-inflammatory drugs
  • Non-narcotic analgesics most of which are also known as non-steroidal anti-inflammatory drugs
  • NSAID non-narcotic analgesic class of drugs
  • Aspirin and acetaminophen have heretofore been included as the pain reliever and fever-reducing component in conventional cough/cold multi- symptom alleviating compositions.
  • non-narcotic agents offering a variety of advantages over these conventionally employed non-narcotic analgesic anti-pyretics.
  • the principal advantages of these non-steroidal anti-inflammatory drugs include not only the clinically superior analgesic, anti-inflammatory and antipyretic activity of these agents compared to aspirin, acetaminophen or phenacetin, but also a minimization of the adverse side affects experienced with these conventional agents; more specifically, the gastrointestinal ulcerations experienced with aspirin and the hepatic toxicity prevalent with the chronic use of acetaminophen.
  • Exemplary prior art cough/cold formulations containing aspirin or acetaminophen include Coricidin ® , Coricidin D ® , Comtrex ® , Dristan ® , Daycare ® , Cotylenol ® , Sinubid ® and the like. These formulations generally contain in addition to aspirin or acetaminophen, one or more antihistaminics, decongestants, cough suppressants, antitussives and expectorants.
  • compositions of matter comprising an analgesically effective amount of a non-steroidal anti-inflammatory drug (NSAID) in combination with at least one of an antihistamine, decongestant, cough suppressant, expectorant and, optionally, including pharmaceutically acceptable carriers therefor.
  • NSAID non-steroidal anti-inflammatory drug
  • Cold-like symptoms refers to coryza, nasal congestion, upper respiratory infections, allergic rhinitis, otitis, sinusitis, etc.
  • Another object of the present invention is to provide suitable dosage unit forms of one or more NSAID' s in combination with at least one of the aforementioned antihistamines, decongestants, etc. adapted for convenient oral administration.
  • non-steroidal anti-inflammatory agents are ideally suited for use in cough/cold formulations by reason of their enhanced analgesic anti-inflammatory and antipyretic activity and low incidence of untoward side effects, particularly at the optimum dosages provided for in the present invention, compared to aspirin or acetaminophen.
  • Naproxen sodium 550 mg was compared with 650 mg of aspirin and was found to provide earlier and better pain relief than aspirin by Sevelius, H. , J. Clin. Pharmacol. 20; 480-485. 1980. "Comparative Analgesic Effects of Naproxen Sodium, Aspirin and Placebo. "
  • Flurbiprofen 50 and 100 mg was significantly more effective than aspirin 600 mg.
  • Flurbiprofen 25 mg was slightly less effective than aspirin 600 mg.
  • NSAID' s non-steroidal anti-inflammatory drugs
  • pharmaceutical compositions and methods of use of the present invention may be selected from any of the following categories:
  • NSAID any non-narcotic analgesic non-steroidal anti-inflammatory compound, including the pharmaceutically acceptable non-toxic salts thereof, falling within one of the five structural categories above but excluding aspirin, acetaminophen and phenacetin.
  • the specific compounds falling within the foregoing definition of the non-steroidal anti-inflammatory drugs for use in the present invention are well known to those skilled in the art and reference may be had to various literature reference sources for their chemical structures, pharmacological activities, side effects, normal dosage ranges, etc. See, for example.
  • propioni ⁇ acid derivatives for use herein, ibuprofen, naproxen, flurbiprofen, fenoprofen, ketoprofen, suprofen, fenbufen, and fluprofen may be mentioned as particularly preferred compounds.
  • acetic acid derivatives Of the acetic acid derivatives, presently preferred members include tolmetin sodium, zomepirac, sulindac and indomethacin.
  • fenamic acid derivatives particularly preferred compounds include mefenamic acid and meclofenamate sodium.
  • the particularly preferred biphenylcarboxylic acid derivatives for use in the present invention include diflunisal and flufenisal.
  • the particularly advantageous oxicams include piroxicam, sudoxicam and isoxicam.
  • any of the foregoing compounds may be utilized in the form of their pharmaceutically acceptable salt forms, e.g., -COO-Na + , -COO-K + , and the like.
  • ibuprofen and naproxen are most preferred.
  • typical effective analgesic amounts of presently preferred NSAID's for use in unit dose compositions of the invention are about 100 - 500 mg diflunisal, about 25 - 100 mg zomepirac sodium, about 50-400 mg ibuprofen, most preferably 100-200 mg, about 125-500 mg naproxen, about 25-100 mg flurbiprofen, about 50-100 mg fenoprofen, about 10-20 mg piroxicam, about 125-250 mg mefenamic acid, about 100-400 mg fenbufen or about 25-50 mg ketoprofen; however, greater or lesser amounts may be employed if desired or necessary.
  • suitable dosage ranges for these compounds will generally
  • NSAID' s including acceptable analgesically effective amounts thereof for use in unit dose compositions of the present invention also appears in applicants United States Patent No. 4,486,436.
  • the cough/cold pharmaceutical compositions of the present invention comprise, in addition to the non-steroidal anti-inflammatory drugs, at least one active ingredient from the following pharmacological classes: antihistamines, sympathomimetics (decon gestants) , cough suppressants-antitussives and expectorants.
  • Typical therapeutically active components from these categories, along with their usual adult dosage, for use in the pharmaceutical compositions and methods of the invention are set forth in the following Table 1.
  • mice Blue Spruce Farm male mice weighing 18-28 grams at the time of testing are used throughout. All mice are dosed orally by gavage with ibuprofen and/or diphenhydramine.
  • the formulation of each test article is a solution or suspension in 0.25% methylcellulose manufactured by Fisher Scientific Company. A dosing volume of 10 ml/mg is used. All doses are coded and the test is performed under a code not known to the observer. Doses are based upon the weights of the animal taken prior to dosing.
  • mice METHOD A phenylquinone writhing assay in mice was conducted over a four day period to test for synergism of the analgesic activity of ibuprofen and diphenhydramine.
  • the assay consists of phenyl-p-benzoquinone (PPQ) introduced in mice thirty minutes post dose of the test treatment (s) .
  • the PPQ is prepared as a .02% aqueous solution in 5 ml ethyl alcohol q.s. to 100 ml with distilled water and is administered intraperitoneally at .25 ml/mouse.
  • the mice are injected with the PPQ solution and are placed in individual plastic squares 4"x4"x5" deep and observed for a ten minute period post treatment dose for exhibition of the writhing syndrome. Complete blocking of the writhing syndrome for the ten minute observation period in any one mouse is considered a positive response for that mouse. Conversely, if the mouse definitely writhes at least once, it is considered to be not protected from the PPQ.
  • mice Three hundred twenty-eight mice were randomly assigned to 40 groups. Two groups of ten mice per series were assigned to a control group (10 prior to the administration of the test treatments and 10 post administration) to verify the ability of the solutions to produce the writhing response.
  • the purpose of the assay on the first day is to estimate the ED 50 (effective dose in 50% of treated mice) of ibuprofen alone and of diphenhydramine alone, and to estimate the relative potency, , of ibuprofen to diphenhydramine, determined as the ratio of the ED 50 of ibuprofen to the ED 50 of diphenhydramine.
  • Eight mice per group are dosed orally (via intubation) with 2, 5, 10 and 20 mg/kg of ibuprofen and 5, 10, 20 and 50 mg/kg of diphenhydramine.
  • Table 2 shows the number of mice protected from writhing activity for each dose of ibuprofen and diphenhydramine.
  • the method of Finney ["Statistical Method of Biological Assay", McMillan
  • Table 3 shows for each of these combination doses, the number of mice protected from writhing activity.
  • the first combination treatment used a ratio of ibuprofen to diphenhydramine of 19:8 and the doses of the constituent drugs in mg/kg that were studied were (8,3) , (12,5), (16,7) and (28,12).
  • the second combination treatment used a ratio of doses of ibuprofen to diphenhydramine of 6:28 and the doses of the constituent drugs in mg/kg that were studied were (3,14), (4.5,21) and (9,42) .
  • the third combination treatment used a ratio of doses of ibuprofen to diphenhydramine of 9:24 and the doses of the constituent drugs in mg/kg that were studied were (3,8), (6,16), (12,32) and (15,40).
  • the fourth combination treatment used a ratio of doses of ibuprofen to diphenhydramine of 4:32 and the doses of the constituent drugs in mg/kg that were studied were (3,24), (3.5,28) (4.5,36) and (5,40).
  • each dose of each combination is equivalent to a dose of ibuprofen, based on the relative potency ( ⁇ ) of diphenhydramine to ibuprofen obtained from the experiment on the first day.
  • the combination of 28 mg/kg of ibuprofen and 12 mg/kg of diphenhydramine is, under the assumption of additivity, equivalent to (28+12 ⁇ ) mg/kg of ibuprofen.
  • Table 4 shows for each dose of each of the combination doses tested the number of mice observed to be protected and the ibuprofen equivalent dose.
  • ED 50 's were estimated based on the observed number of mice protected at each ibuprofen equivalent dose using the method of Finney.
  • Table 5 displays the estimated ED 50 's for each ratio.
  • the surprising synergistic effects of combining ibuprofen with diphenhydramine can be seen from the results of Tables 4 and 5 and the Figure of Drawing.
  • the Figure of Drawing summarizes all of the findings by depicting the ED 50 's obtained for each treatment alone, the ED 50 line if the treatments were additive, the number of mice/protected from writhing for each treatment studied and the estimated ED 50 's for each combination ratio.
  • the ED 50 of ibuprofen alone is estimated to be 24 mg/kg and for diphenhydramine to be 38 mg/kg.
  • the relative potency of diphenhydramine to ibuprofen is 24/38.
  • synergism appears to be present for four ratios, and these ratios were further investigated on days 3 and
  • the ED 50 's were found to be for the dosage ratio of 19:8, 23 mg/kg of ibuprofen, for the dosage ratio 6:28, 19 mg/kg of ibuprofen, for the dosage ratio 9:24, 18 mg/kg of ibuprofen, and for the dosage ratio 4:32, 23 mg/kg of ibuprofen.
  • Two of these ED 50 's are substantially less than 24 mg/kg of ibuprofen which is the ED 50 that would be expected if the effects were additive. This represents a 25% reduction of the amount of ibuprofen that is required to obtain the effect in 50% of the animals.
  • the Figure of Drawing indicates that many other dose ratios as well would produce an unexpected synergistic effect.
  • the foregoing active ingredients will be combined with the non-steroidal anti-inflammatory drug(s) and will typically be administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, i.e., oral tablets, capsules, elixirs, syrups, etc. and consistent with conventional pharmaceutical practices.
  • carrier suitable pharmaceutical diluents, excipients or carriers
  • the active drug components may be combined with any oral non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, ethyl alcohol (liquid forms) and the like.
  • suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated in the mixture.
  • suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes.
  • lubricants there may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, etc.
  • Disintegrators include, without limitation, starch, methylcellulose, agar, bentonite, guar gum, etc. Sweetening and flavoring agents and preservatives can also be included where appropriate.
  • compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components to optimize the therapeutic effects, i.e., analgesia, antihistaminic, etc. while minimizing undesirable side effects.
  • Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
  • Triturate active ingredients and q.s. with lactose to selected capsule size Triturate active ingredients and q.s. with lactose to selected capsule size

Abstract

Pharmaceutical compositions and methods of using same comprising a non-steroidal anti-inflammatory drug in combination with at least one other active component selected from an antihistamine, decongestant, cough suppressant (antitussive) or expectorant are provided for the relief of cough, cold and cold-like symptoms.

Description

COUGH/COLD MIXTURES COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Background of the Invention The present invention relates generally to novel pharmaceutical compositions of matter comprising one or more non-steroidal anti-inflammatory drugs (NSAID) in combination with at least one antihistamine, sympathomimetic drug (nasal decongestant, bronchodilator) cough suppressant and/or expectorant, optionally in combination with suitable pharmaceutically acceptable non-toxic carriers or excipients, and to methods of using said compositions in the treatment, management or mitigation of cough, cold, cold-like and/or flu symptoms and the discomfort, pain, fever and general malaise associated therewith.
Non-narcotic analgesics, most of which are also known as non-steroidal anti-inflammatory drugs
(NSAID) , are widely administered orally in the treatment of mild to severe pain. Within this class, the compounds vary widely in their chemical structure and in their biological profiles as analgesics, anti-inflammatory agents and antipyretic agents. Among the most commonly used members of the non-narcotic analgesic class of drugs are aspirin, acetaminophen and phenacetin. Aspirin and acetaminophen have heretofore been included as the pain reliever and fever-reducing component in conventional cough/cold multi- symptom alleviating compositions.
However, a number of alternative non-narcotic agents offering a variety of advantages over these conventionally employed non-narcotic analgesic anti-pyretics have now been developed. The principal advantages of these non-steroidal anti-inflammatory drugs include not only the clinically superior analgesic, anti-inflammatory and antipyretic activity of these agents compared to aspirin, acetaminophen or phenacetin, but also a minimization of the adverse side affects experienced with these conventional agents; more specifically, the gastrointestinal ulcerations experienced with aspirin and the hepatic toxicity prevalent with the chronic use of acetaminophen.
Exemplary prior art cough/cold formulations containing aspirin or acetaminophen include Coricidin®, Coricidin D®, Comtrex®, Dristan®, Daycare®, Cotylenol®, Sinubid® and the like. These formulations generally contain in addition to aspirin or acetaminophen, one or more antihistaminics, decongestants, cough suppressants, antitussives and expectorants.
While aspirin and acetaminophen have been utilized in these previous compositions, it has not been heretofore proposed to use any of the newer non-steroidal anti-inflammatory drugs (i.e., excluding aspirin, acetaminophen and phenacetin) in the preparation of advantageous cough/cold pharmaceutical compositions.
Summary of the Invention It is, therefore, a primary object of the present invention to provide pharmaceutical compositions of matter comprising an analgesically effective amount of a non-steroidal anti-inflammatory drug (NSAID) in combination with at least one of an antihistamine, decongestant, cough suppressant, expectorant and, optionally, including pharmaceutically acceptable carriers therefor.
It is a further object of the present invention to provide methods for the symptomatic relief of cough, cold, cold-like and flu symptoms by the administration of preselected dosages of the pharmaceutical compositions of the present invention. Cold-like symptoms as used herein refers to coryza, nasal congestion, upper respiratory infections, allergic rhinitis, otitis, sinusitis, etc.
Another object of the present invention is to provide suitable dosage unit forms of one or more NSAID' s in combination with at least one of the aforementioned antihistamines, decongestants, etc. adapted for convenient oral administration.
Brief Description of the Drawing The Figure of Drawing is a plot of dose of diphenhydramine versus dose of ibuprofen in the phenylquinone writhing assay to indicate the number of mice protected.
Detailed Description of the Invention More specifically, the applicants herein have found that certain non-steroidal anti-inflammatory agents are ideally suited for use in cough/cold formulations by reason of their enhanced analgesic anti-inflammatory and antipyretic activity and low incidence of untoward side effects, particularly at the optimum dosages provided for in the present invention, compared to aspirin or acetaminophen.
The superiority of various of the non-narcotic analgesics belonging to the non-steroidal anti-inflammatory drug class in comparative studies with aspirin and acetaminophen is well documented in the literature.
Cooper in 1977 found that ibuprofen 400 mg had a greater peak effect and longer duration of action than aspirin 650 mg. Cooper, S.A., Needle, A.E., Kruger, G.O. 1977. "An Analgesic Relative Potency Assay Comparing Aspirin, Ibuprofen and Placebo. "J. Oral Surg. 35;898-903. Cooper in another study in 1982 found 400 mg of ibuprofen to be more effective than aspirin 650 mg. Cooper, S.A., Engel, J., Ladov, M. , Precheur, H., Rosenheck, A., Rauch, D. 1982. "Analgesic Efficacy of an Ibuprofen-codeine Combination." Pharmacotherapy 2;162-67. Sunshine et al found ibuprofen to be significantly superior to aspirin in the relief of post-episiotomy pain. Sunshine, A. et al. Clinical Pharmacology and Therapeutics, :24;254-250, 1983.
Dionne in 1982 found ibuprofen to be more effective than acetaminophen in delaying the onset and intensity of post-operative dental pain. Dionne, R.A., Campbell, R.A., Cooper, S.A., Hall, D.L., Buckingham, B. "Suppression of Post operative Pain by Preoperative Administration of Ibuprofen in Comparison to Placebo, Acetaminophen and Acetaminophen Plus Codeine." J. Clin. Phamacol. (In press) .
Naproxen sodium 550 mg was compared with 650 mg of aspirin and was found to provide earlier and better pain relief than aspirin by Sevelius, H. , J. Clin. Pharmacol. 20; 480-485. 1980. "Comparative Analgesic Effects of Naproxen Sodium, Aspirin and Placebo. "
Flurbiprofen 50 and 100 mg was significantly more effective than aspirin 600 mg. Flurbiprofen 25 mg was slightly less effective than aspirin 600 mg.
Sunshine, A., Olson N.Z., Laska, E.M. Zighelboim, I., DeCastro, A., Desarrazin, C. , Pharmaco Ther.3:177-181. " Analgesic Effect of Graded Doses of Flurbiprofen in Postepisiotomy Pain". Silberman found suprofen 200 mg more effective than aspirin 650 mg for pain relief in the treatment of moderate to severe pain resulting from musculoskeletal pain. Silberman, H.M. "Multiple-Dose Comparison of Suprofen, Aspirin and Placebo in the
Treatment of Musculoskeletal Pain." Pharmacology 27 :S 1, 65-73 (1983).
While these reported findings with respect to the outstanding analgesic properties of the non- steroidal anti-inflammatory drugs compared to aspirin or acetaminophen have prompted the widespread acceptance and usage of these newer non-narcotic analgesics, as single entities, for the treatment and management of acute and chronic inflammatory states, notably rheumatoid arthritis and osteoarthritis, the utilization of these agents in cough/cold compositions has not heretofore been considered.
The non-steroidal anti-inflammatory drugs (NSAID' s) for use in the pharmaceutical compositions and methods of use of the present invention may be selected from any of the following categories:
(1) The propionic acid derivatives;
(2) The acetic acid derivatives;
(3) The fenamic acid derivatives; (4) The biphenylcarboxylic acid derivatives; and
(5) The oxicams.
Accordingly, the term "NSAID" as used herein is intended to mean any non-narcotic analgesic non-steroidal anti-inflammatory compound, including the pharmaceutically acceptable non-toxic salts thereof, falling within one of the five structural categories above but excluding aspirin, acetaminophen and phenacetin. The specific compounds falling within the foregoing definition of the non-steroidal anti-inflammatory drugs for use in the present invention are well known to those skilled in the art and reference may be had to various literature reference sources for their chemical structures, pharmacological activities, side effects, normal dosage ranges, etc. See, for example. Physician's Desk Reference, 35th Edition, 1981 and The Merck Index, 9th Edition, Merck and Company, Rahway, New Jersey (1976) and Cutting's Handbook of Pharmacology, 6th Edition, Ed. T. Z. Czacky, M.D. , Appleton-Century-Crofts, New York, 1979, Chapter 49:538-550.
Of the propioniσ acid derivatives for use herein, ibuprofen, naproxen, flurbiprofen, fenoprofen, ketoprofen, suprofen, fenbufen, and fluprofen may be mentioned as particularly preferred compounds.
Of the acetic acid derivatives, presently preferred members include tolmetin sodium, zomepirac, sulindac and indomethacin.
Of the fenamic acid derivatives, particularly preferred compounds include mefenamic acid and meclofenamate sodium.
The particularly preferred biphenylcarboxylic acid derivatives for use in the present invention include diflunisal and flufenisal.
The particularly advantageous oxicams include piroxicam, sudoxicam and isoxicam.
Of course, it will be appreciated by those skilled in the art, that any of the foregoing compounds may be utilized in the form of their pharmaceutically acceptable salt forms, e.g., -COO-Na+, -COO-K+, and the like. Of the foregoing non-steroidal anti- inflammatory drugs, in the practice of the preferred embodiments of the present invention, ibuprofen and naproxen are most preferred. With respect to the dosage amount of the non-steroidal anti-inflammatory drugs in the compositions of the invention, although the specific dose will vary depending upon the age and weight of the patient, the severity of the symptoms, the incidence of side effects and the like, for humans, typical effective analgesic amounts of presently preferred NSAID's for use in unit dose compositions of the invention are about 100 - 500 mg diflunisal, about 25 - 100 mg zomepirac sodium, about 50-400 mg ibuprofen, most preferably 100-200 mg, about 125-500 mg naproxen, about 25-100 mg flurbiprofen, about 50-100 mg fenoprofen, about 10-20 mg piroxicam, about 125-250 mg mefenamic acid, about 100-400 mg fenbufen or about 25-50 mg ketoprofen; however, greater or lesser amounts may be employed if desired or necessary. With respect to the compounds set forth hereinabove falling within the propionic acid derivative category, suitable dosage ranges for these compounds will generally fall within the range of 25 mg to 600 mg in each unit dose. A complete description of the various
NSAID' s, including acceptable analgesically effective amounts thereof for use in unit dose compositions of the present invention also appears in applicants United States Patent No. 4,486,436. The cough/cold pharmaceutical compositions of the present invention comprise, in addition to the non-steroidal anti-inflammatory drugs, at least one active ingredient from the following pharmacological classes: antihistamines, sympathomimetics (decon gestants) , cough suppressants-antitussives and expectorants. Typical therapeutically active components from these categories, along with their usual adult dosage, for use in the pharmaceutical compositions and methods of the invention are set forth in the following Table 1.
Figure imgf000011_0001
Figure imgf000012_0001
Figure imgf000013_0001
Among such Table 1 antihistamines, sympathomimetics, cough suppressants-antitussives and expectorants, in combination with a non-steroidal anti-inflammatory drug, applicants have already demonstrated a synergistically enhanced analgesic and anti-inflammatory response in a mammalian organism, as shown below in Example 1.
Example 1 - Pharmacologic Test for Synergism - Ibuprofen/Diphenhydramine.
The unexpected synergistic analgesic effect of the addition of diphenhydramine to ibuprofen is evidenced by tests conducted on mice. Blue Spruce Farm male mice weighing 18-28 grams at the time of testing are used throughout. All mice are dosed orally by gavage with ibuprofen and/or diphenhydramine. The formulation of each test article is a solution or suspension in 0.25% methylcellulose manufactured by Fisher Scientific Company. A dosing volume of 10 ml/mg is used. All doses are coded and the test is performed under a code not known to the observer. Doses are based upon the weights of the animal taken prior to dosing.
METHOD A phenylquinone writhing assay in mice was conducted over a four day period to test for synergism of the analgesic activity of ibuprofen and diphenhydramine.
The assay consists of phenyl-p-benzoquinone (PPQ) introduced in mice thirty minutes post dose of the test treatment (s) . The PPQ is prepared as a .02% aqueous solution in 5 ml ethyl alcohol q.s. to 100 ml with distilled water and is administered intraperitoneally at .25 ml/mouse. The mice are injected with the PPQ solution and are placed in individual plastic squares 4"x4"x5" deep and observed for a ten minute period post treatment dose for exhibition of the writhing syndrome. Complete blocking of the writhing syndrome for the ten minute observation period in any one mouse is considered a positive response for that mouse. Conversely, if the mouse definitely writhes at least once, it is considered to be not protected from the PPQ.
Three hundred twenty-eight mice were randomly assigned to 40 groups. Two groups of ten mice per series were assigned to a control group (10 prior to the administration of the test treatments and 10 post administration) to verify the ability of the solutions to produce the writhing response.
The purpose of the assay on the first day is to estimate the ED50 (effective dose in 50% of treated mice) of ibuprofen alone and of diphenhydramine alone, and to estimate the relative potency, , of ibuprofen to diphenhydramine, determined as the ratio of the ED50 of ibuprofen to the ED50 of diphenhydramine. Eight mice per group are dosed orally (via intubation) with 2, 5, 10 and 20 mg/kg of ibuprofen and 5, 10, 20 and 50 mg/kg of diphenhydramine. Table 2 shows the number of mice protected from writhing activity for each dose of ibuprofen and diphenhydramine. The method of Finney ["Statistical Method of Biological Assay", McMillan
Pub., 3rd Edition, 1978] is used to estimate the ED50's of ibuprofen alone and diphenhydramine alone.
On the second day eight combination doses were studied. The doses were chosen based upon the ED50's established in the preceding day's experiment, which, under the assumption of additivity, would provide protection for 50% of the mice. These doses were tested in order to observe those ratio (s) of the combination drugs that would yield a synergistic effect. Combinations for which five or more mice exhibit blockage of writhing are candidates for further study. The doses of the constituent drugs in mg/kg for the eight groups were for ibuprofen (I) and diphenhydramine (D) respectively, [abbreviated as (I,D)]: (22,4), (19,8), (16,12), (14,6), (11,20), (9,24), (6,28), (4,32). Table 3 shows for each of these combination doses, the number of mice protected from writhing activity. On the third and fourth days the four specific fixed ratios that achieved 5 or more protected mice were studied in more detail, i.e., the first combination treatment used a ratio of ibuprofen to diphenhydramine of 19:8 and the doses of the constituent drugs in mg/kg that were studied were (8,3) , (12,5), (16,7) and (28,12). The second combination treatment used a ratio of doses of ibuprofen to diphenhydramine of 6:28 and the doses of the constituent drugs in mg/kg that were studied were (3,14), (4.5,21) and (9,42) . The third combination treatment used a ratio of doses of ibuprofen to diphenhydramine of 9:24 and the doses of the constituent drugs in mg/kg that were studied were (3,8), (6,16), (12,32) and (15,40). The fourth combination treatment used a ratio of doses of ibuprofen to diphenhydramine of 4:32 and the doses of the constituent drugs in mg/kg that were studied were (3,24), (3.5,28) (4.5,36) and (5,40).
Under the assumption of additivity each dose of each combination is equivalent to a dose of ibuprofen, based on the relative potency (ρ) of diphenhydramine to ibuprofen obtained from the experiment on the first day. Thus, for example, in the dose ratio 19:8 the combination of 28 mg/kg of ibuprofen and 12 mg/kg of diphenhydramine is, under the assumption of additivity, equivalent to (28+12ρ) mg/kg of ibuprofen. Table 4 shows for each dose of each of the combination doses tested the number of mice observed to be protected and the ibuprofen equivalent dose. For each of the four combination ratios, ED50's were estimated based on the observed number of mice protected at each ibuprofen equivalent dose using the method of Finney. Table 5 displays the estimated ED50's for each ratio.
RESULTS
The surprising synergistic effects of combining ibuprofen with diphenhydramine can be seen from the results of Tables 4 and 5 and the Figure of Drawing. The Figure of Drawing summarizes all of the findings by depicting the ED50's obtained for each treatment alone, the ED50 line if the treatments were additive, the number of mice/protected from writhing for each treatment studied and the estimated ED50's for each combination ratio. The ED50 of ibuprofen alone is estimated to be 24 mg/kg and for diphenhydramine to be 38 mg/kg. The relative potency of diphenhydramine to ibuprofen is 24/38. Among the 8 ratios tested on the second day, synergism appears to be present for four ratios, and these ratios were further investigated on days 3 and
4. The ED50's were found to be for the dosage ratio of 19:8, 23 mg/kg of ibuprofen, for the dosage ratio 6:28, 19 mg/kg of ibuprofen, for the dosage ratio 9:24, 18 mg/kg of ibuprofen, and for the dosage ratio 4:32, 23 mg/kg of ibuprofen. Two of these ED50's are substantially less than 24 mg/kg of ibuprofen which is the ED50 that would be expected if the effects were additive. This represents a 25% reduction of the amount of ibuprofen that is required to obtain the effect in 50% of the animals. The Figure of Drawing indicates that many other dose ratios as well would produce an unexpected synergistic effect.
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
In the pharmaceutical compositions and methods of the present invention, the foregoing active ingredients will be combined with the non-steroidal anti-inflammatory drug(s) and will typically be administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, i.e., oral tablets, capsules, elixirs, syrups, etc. and consistent with conventional pharmaceutical practices. For instance, for oral administration in the form of tablets or capsules, the active drug components may be combined with any oral non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, ethyl alcohol (liquid forms) and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated in the mixture. Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes. Among the lubricants there may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, etc. Disintegrators include, without limitation, starch, methylcellulose, agar, bentonite, guar gum, etc. Sweetening and flavoring agents and preservatives can also be included where appropriate.
Of course, additionally, the compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components to optimize the therapeutic effects, i.e., analgesia, antihistaminic, etc. while minimizing undesirable side effects. Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
As representative suitable formulations consistent with the objects, features and advantages of the present invention, the following non-limiting examples are provided.
Example 2
Ibuprofen - 200 mg Chlorpheniramine maleate - 8 mg
Phenylpropanolamine hydrochloride - 8 mg Dextromethorphan hydrobromide - 30 mg Guaifenesin - 100 mg
Triturate active ingredients and q.s. with lactose to selected capsule size
Example 3
In each fluid ounce:
Naproxen (sodium) 250 mg, dextromethorphan HB 30 mg, phenylpropanolamine hydrochloride 25 mg, orange flavoring and alcohol 10% v/v.
From the foregoing, other typical acceptable pharmaceutical formulations will be apparent to those skilled in the art of pharmaceutical formulations. While the invention has been described and illustrated with reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit of the invention. For example, effective dosages other than the preferred ranges set forth hereinabove with respect to the active ingredients may be applicable as a consequence of variations of the responsiveness of the mammal treated, severity of symptoms, dosage related adverse effects, if any, observed and similar considerations. Accordingly, such expected variations or differences in the practice of the present invention and the results obtained are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore that the invention be limited only by the scope of the claims which follow.

Claims

CLAIMS :
1. In a pharmaceutical composition comprising an analgesic in combination with at least one of an antihistamine, decongestant, cough suppressant or expectorant, the improvement comprising an analgesically effective amount of a non-steroidal anti-inflammatory drug or pharmaceutically acceptable salt thereof as the analgesic component.
2. A composition according to Claim 1, wherein said non-steroidal anti-inflammatory drug is selected from a propionic acid derivative, an acetic acid derivative, a fenamic acid derivative, a biphenylcarboxylie acid derivative, an oxicam or the pharmaceutically acceptable salts thereof.
3. A composition according to Claim 2, wherein said non-steroidal anti-inflammatory drug comprises a propionic acid derivative selected from ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, trioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen, or bucloxic acid.
4. A composition according to Claim 3, wherein said drug is ibuprofen or naproxen.
5. A composition according to Claim 3, wherein said analgesically effective amount of said drug comprises between about 50 mg to 600 mg in each unit dose thereof.
6. A composition according to Claim 2, wherein said non-steroidal anti-inflammatory drug comprises an acetic acid derivative selected from indomethacin, sulindac, tolmetin, zomepirac, diclofenac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac or oxpinac.
7. A composition according to Claim 6 wherein said analgesiσally effective amount of said drug ranges between about 25 to 400 mg in each unit dose thereof.
8. A composition according to Claim 2 wherein said fenamic acid derivative is selected from mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid or tolfenamic acid.
9. A composition according to Claim 8, wherein said analgesically effective amount of said drug ranges between about 250 to 500 mg in each unit dose thereof.
10. A composition according to Claim 2 wherein said non-steroidal anti-inflammatory drug comprises a biphenylcarboxylic acid derivative selected from diflunisal or flufenisal.
11. A composition according to Claim 10, wherein said analgesiσally effective amount of said drug ranges between about 250 to 500 mg in each unit dose thereof.
12. A composition according to Claim 2, wherein said non-steroidal anti-inflammatory drug com prises an oxicam selected from piroxicam, sudoxicam, or isoxicam.
13. A composition according to Claim 12 wherein said analgesically effective amount of said drug ranges between about 10 to 20 mg in each unit dose thereof.
14. A composition of matter according to Claim 1, wherein said antihistamine is selected from chlorpheniramine, brompheniramine, dexchlorpheniramine, dexbrompheniramine, triprolidine, diphenhydramine, doxylamine, tripelennamine, cyproheptadine, carbinoxamine, bromodiphenydramine, phenyltoloxamine, phenindamine, pyrilamine or azatadine.
15. A composition according to Claim 1 wherein said decongestant is selected from pseudoephedrine, phenylpropanolamine, or phenylephrine.
16. A composition according to Claim 1 wherein said cough suppressant is selected from caramiphen, dextromethorphan or codeine.
17. A composition according to Claim 1 wherein said expectorant is selected from terpin hydrate, guaifenesin, potassium iodide, potassium citrate or potassium guaiacolsulfonate.
18. A composition according to Claim 1 further comprising a pharmaceutically acceptable non-toxic carrier.
19. A composition according to Claim 18 adapted for oral administration in tablet, capsule or liquid form.
20. A method of alleviating cough, cold and cold-like symptoms in a mammal in need thereof, comprising administering thereto a symptom alleviating amount of a composition according to Claim 1.
PCT/US1985/000596 1984-04-09 1985-04-08 Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs WO1985004589A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AT85901895T ATE72989T1 (en) 1984-04-09 1985-04-08 COUGH AND/OR COLD MIXTURES CONTAINING NON-STEROID ANTI-INFLAMMATORY MEDICATIONS.
DE8585901895T DE3585495D1 (en) 1984-04-09 1985-04-08 MIXTURES AGAINST Cough and / or Colds Containing Non-Steroids Anti-Inflammatory Drugs.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/598,502 US4552899A (en) 1984-04-09 1984-04-09 Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US598,502 1984-04-09

Publications (1)

Publication Number Publication Date
WO1985004589A1 true WO1985004589A1 (en) 1985-10-24

Family

ID=24395811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1985/000596 WO1985004589A1 (en) 1984-04-09 1985-04-08 Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs

Country Status (9)

Country Link
US (11) US4552899A (en)
EP (1) EP0180597B1 (en)
JP (1) JP2848556B2 (en)
AT (1) ATE72989T1 (en)
AU (2) AU589554B2 (en)
CA (1) CA1258430A (en)
DE (1) DE3585495D1 (en)
WO (1) WO1985004589A1 (en)
ZA (1) ZA852485B (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241615A1 (en) * 1986-04-15 1987-10-21 Warner-Lambert Company A pharmaceutical composition of phenindamine having enhanced release characteristics
EP0295212A2 (en) * 1987-06-10 1988-12-14 Warner-Lambert Company Process for preparing a pharmaceutical composition
EP0316434A1 (en) * 1987-06-08 1989-05-24 Abraham Sunshine Cough/cold mixtures comprising non-sedating antihistamine drugs.
EP0348683A1 (en) * 1988-06-01 1990-01-03 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions containing ibuprofen in combination with a piperidinoalkanol antihistamine
EP0384514A2 (en) * 1989-02-21 1990-08-29 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
WO1991000088A1 (en) * 1989-06-23 1991-01-10 Boehringer Ingelheim France Novel use of 1-phenyl-2-aminoethanol derivatives as healing agents
EP0413171A1 (en) * 1989-08-17 1991-02-20 Dolorgiet GmbH & Co. KG Strong analgesic composition and process for its preparation
WO1992004021A1 (en) * 1990-09-11 1992-03-19 Richardson Vicks Inc. Method for providing improved analgesic effect
WO1992004022A1 (en) * 1990-09-11 1992-03-19 Richardson Vicks Inc. Use of compositions containing 2-(6'-substituted-2'-naphthyl)-acetic acid derivatives for the treatment of respiratory disorders
WO1992015332A1 (en) * 1991-03-04 1992-09-17 Warner-Lambert Company Novel salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms
US5164398A (en) * 1991-04-01 1992-11-17 Merck & Co., Inc. Ibuprofen-antitussive combinations
EP0566393A1 (en) * 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
WO1994014476A1 (en) * 1992-12-21 1994-07-07 The Procter & Gamble Company Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders
WO1994018970A1 (en) * 1993-02-18 1994-09-01 Warner-Lambert Company Cold/sinus preparation consisting of phenindamine tartarate with or without therapeutic agents
EP0631782A1 (en) * 1993-06-30 1995-01-04 Takeda Chemical Industries, Ltd. Stabilized solid pharmaceutical preparation containing dextromethorphan, phenylpropanolamine and caffeine
WO1995004058A1 (en) * 1993-07-29 1995-02-09 Les Laboratoires Meram 2-(3-benzoylphenyl)propionic acid codeine salt, preparation method therefor and pharmaceutical compositions containing said salt
WO1997004808A1 (en) * 1995-07-28 1997-02-13 The Procter & Gamble Company Compositions containing analgesics and antihistamines and methods for treating respiratory disorders
WO1997006801A1 (en) * 1995-08-18 1997-02-27 Parke Davis Composition containing mefenamic acid in association with codeine
FR2741264A1 (en) * 1995-11-16 1997-05-23 Parke Davis Compsn. contg. fenamic acid deriv. and codeine
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
WO1998048839A1 (en) * 1997-04-30 1998-11-05 Warner-Lambert Company Topical nasal antiinflammatory compositions
WO1999066919A1 (en) * 1998-06-19 1999-12-29 Mcneil-Ppc, Inc. Pharmaceutical composition containing a salt of acetaminophen and at least one other active ingredient
WO2001070205A2 (en) * 2000-03-23 2001-09-27 Smithkline Beecham P.L.C. Composition comprising paracetamol and niflumic acid
WO2001074341A2 (en) * 2000-03-30 2001-10-11 Schering Corporation Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
EP1255544A1 (en) * 2000-01-31 2002-11-13 Magainin Pharmaceuticals, Inc. Mucin synthesis inhibitors
WO2002096406A1 (en) * 2001-05-25 2002-12-05 Ssp Co., Ltd. Medicinal compositions
WO2003068203A1 (en) * 2002-01-30 2003-08-21 Zentiva, A.S. Use of a combination of a non-steroidal anti-inflammatory agent and guaifenesin for the treatment of acute pain
WO2004058236A1 (en) * 2002-12-20 2004-07-15 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
EP1572206A2 (en) * 2002-12-18 2005-09-14 Wyeth Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
EP2050435A1 (en) 2007-10-18 2009-04-22 Renate Conrad Cough mixture
GB2475359A (en) * 2009-11-11 2011-05-18 Biocopea Ltd A compound for use in treating a fulminant respiratory disorder
US8304405B2 (en) 2002-06-14 2012-11-06 Cipla Limited Combination of azelastine and ciclesonide for nasal administration
WO2016063057A1 (en) * 2014-10-21 2016-04-28 Reckitt Benckiser Llc Novel pharmaceutical formulation
WO2017062997A1 (en) * 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation
WO2022119431A1 (en) * 2020-12-04 2022-06-09 Laboratorios Silanes S.A. De C.V. Pharmaceutical composition having an analgaesic and an antihistamine for treating respiratory diseases

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522826A (en) * 1984-02-08 1985-06-11 Richardson-Vicks Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4783465A (en) * 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US5260333A (en) * 1986-08-08 1993-11-09 Bristol Myers Squibb Company Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
GB8629567D0 (en) * 1986-12-10 1987-01-21 Boots Co Plc Therapeutic agents
US4810502A (en) * 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US5023076A (en) * 1987-02-27 1991-06-11 Alza Corporation Lamina comprising carboxyvinyl polymer
US4915952A (en) * 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US4861797A (en) * 1987-10-15 1989-08-29 Oratech Pharmaceutical Development Corporation Liquid ibuprofen compositions and methods of making them
US4859704A (en) * 1987-10-15 1989-08-22 Oratech Pharmaceutical Development Corporation Water soluble ibuprofen compositions and methods of making them
US4883818A (en) * 1987-11-17 1989-11-28 Analgesic Associates Onset-hastened/enhanced analgesia
US4927854A (en) * 1987-12-24 1990-05-22 Analgesic Associates Sustained/enhanced analgesia
US5286751A (en) * 1987-12-24 1994-02-15 Analgesic Associates Sustained/enhanced antipyretic response
US4826903A (en) * 1988-02-22 1989-05-02 Eastman Kodak Company Condensation polymer containing the residue of an acyloxystyrl compound and shaped articles produced therefrom
US4933172A (en) * 1988-10-06 1990-06-12 Warner-Lambert Co. Method of and compositions for treating destructive periodontal disease
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5134165A (en) * 1989-06-09 1992-07-28 Hirsch Kauffmann Dan J Method of treatment for loss of vision due to ophthalmic surgery
US5580577A (en) * 1990-01-11 1996-12-03 Herzenberg; Leonard A. Method of treating the symptoms of human rhinovirus infection
US5036067A (en) * 1990-03-14 1991-07-30 Merck & Co., Inc. Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
US5260073A (en) * 1990-05-21 1993-11-09 Norwich Eaton Pharmaceuticals, Inc. Use of phenylpropanolamine as a mucus secretogogue in the upper airways
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5179097A (en) * 1991-06-10 1993-01-12 Angres Isaac A Salts of non-steroidal anti-inflammatory carboxylic acids and anti-lipidemic carboxylic acids
ZA933725B (en) * 1992-05-28 1993-12-15 Elan Corp Plc Tablet formulation
PT815860E (en) 1992-08-03 2006-08-31 Sepracor Inc TERFENADINE CARBOXYLATE AND TREATMENT OF ALLERGIC DISORDERS.
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
EP0692975A4 (en) * 1993-04-08 2000-11-29 Univ Queensland Administration of vaso-active agent and therapeutic agent
US5451401A (en) * 1993-09-29 1995-09-19 The Procter & Gamble Company Diphosphonic acid esters as tartar control agents
ATE259232T1 (en) * 1995-03-03 2004-02-15 Endo Pharmaceuticals Inc USE OF DEXTROMETHORPHAN OR DEXTRORPHANE TO TREAT URINARY INCONTINENCE
US5840731A (en) * 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
US5648358A (en) * 1996-03-05 1997-07-15 Mitra; Sekhar Compositions and methods for treating respiratory disorders
US6348216B1 (en) * 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6361794B1 (en) 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US5998478A (en) * 1997-01-15 1999-12-07 Platt; Chris E. Timed release tablet comprising naproxen and pseudoephedrine
US5859060A (en) * 1997-01-15 1999-01-12 Platt; Chris Timed release tablet comprising naproxen and pseudoepherine
RS49982B (en) 1997-09-17 2008-09-29 Euro-Celtique S.A., Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US6037358A (en) * 1999-03-24 2000-03-14 Carter-Wallace, Inc. Decongestant/antihistaminic compositions
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US20040234457A1 (en) * 1999-10-19 2004-11-25 The Procter & Gamble Company Methods of preventing and treating SARS using low pH respiratory tract compositions
US20040033260A1 (en) * 1999-10-19 2004-02-19 The Procter & Gamble Company Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc
US6114346A (en) 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
SK287684B6 (en) 1999-12-20 2011-06-06 Schering Corporation Sustained release solid oral pharmaceutical dosage composition
SK287105B6 (en) 1999-12-20 2009-12-07 Schering Corporation Bilayer sustained release oral dosage composition
US6099860A (en) * 2000-01-21 2000-08-08 Platt; Chris E. Controlled release oral preparation with naproxen sodium and pseudoephedrine
US20020147216A1 (en) * 2000-01-31 2002-10-10 Yuhong Zhou Mucin synthesis inhibitors
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
SE0000773D0 (en) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (en) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6586469B2 (en) 2000-07-25 2003-07-01 Medpointe Healthcare Inc. Antihistaminic/antitussive compositions
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6566396B2 (en) 2000-11-30 2003-05-20 Medpointe Healthcare Inc. Antitussive/antihistaminic compositions
US20020177626A1 (en) 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
US7273623B2 (en) * 2001-10-12 2007-09-25 Kiel Laboratories, Inc. Process for preparing tannate tablet, capsule or other solid dosage forms
US6869618B2 (en) 2001-04-10 2005-03-22 Kiel Laboratories, Inc. Process for preparing tannate liquid and semi-solid dosage forms
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
JP4756823B2 (en) * 2001-06-01 2011-08-24 ポーゼン インコーポレイテッド Pharmaceutical composition for coordinated delivery of NSAIDs
BR0211794A (en) * 2001-07-31 2004-11-03 Wyeth Corp Pharmaceutical composition and method for masking the taste of at least one unpleasant tasting pharmaceutically active compound
US20030044461A1 (en) * 2001-08-22 2003-03-06 Carter-Wallace, Inc. Antitussive/expectorant compositions
US20030060422A1 (en) 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
US6509492B1 (en) 2001-08-31 2003-01-21 First Horizon Pharmaceutical Corporation Tannate compositions and methods of treatment
SE0102993D0 (en) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040132827A1 (en) * 2001-10-26 2004-07-08 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
CA2469736A1 (en) * 2002-04-09 2003-10-23 Kiel Laboratories, Inc. Diphenhydramine tannate solid dose compositions and methods of use
EA007156B1 (en) 2002-04-15 2006-08-25 Адамс Лэборетриз, Инк. Sustained release of guaifenesin combination drugs
US7148376B2 (en) * 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
US20040162273A1 (en) * 2003-01-23 2004-08-19 The Procter & Gamble Company Powder pharmaceutical compositions
EP1628656B1 (en) * 2003-03-25 2008-10-15 Kiel Laboratories, Inc. Gabapentin tannate in liquid and/or semi-solid dosage forms
EP1622603A4 (en) * 2003-03-25 2010-03-24 Kiel Lab Inc Phenolic acid salts of gabapentin in solid dosage forms and methods of use
WO2004093866A1 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Process for preparing phenolic acid salts of gabapentin
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
GB0312419D0 (en) * 2003-05-30 2003-07-02 Boots Healthcare Int Ltd Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess
US20050037979A1 (en) * 2003-06-05 2005-02-17 Ping Jeffrey H. Tannate compositions and methods of use
US6954474B2 (en) * 2003-06-27 2005-10-11 Optical Communications Products, Inc. Method and apparatus for backside monitoring of VCSELs
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050232987A1 (en) * 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
US20050137262A1 (en) * 2003-12-22 2005-06-23 Hu Patrick C. Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
US20070190125A1 (en) 2004-03-03 2007-08-16 Constantine Georgiades Positioning feature for aiding use of film or strip product
US20070110676A1 (en) * 2005-11-17 2007-05-17 The Procter & Gamble Company Compositions useful for prevention and treatment of common cold and influenza-like symptoms
DK2428205T3 (en) 2006-03-16 2012-10-22 Tris Pharma Inc MODIFIED FORMULATIONS CONTAINING PHARMACEUTICAL ION EXCHANGE RESIN COMPLEX
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
CL2007002425A1 (en) * 2006-08-22 2008-06-27 Albermarle Corp PROCEDURE OF CONTROLLED PREPARATION OF SODIUM SALT OF IBUPROFEN OF SIZE OF MEDIUM PARTICLE; AND SUCH SODIUM SALT PARTICLES.
CA2669410C (en) 2006-11-21 2015-07-14 Mcneil-Ppc, Inc. Modified release analgesic suspensions
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
US20080305159A1 (en) * 2007-06-06 2008-12-11 Mikart, Inc. Ibuprofen-Hydrocodone-Antihistamine Composition
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
AU2008280801B2 (en) * 2007-07-23 2014-03-06 Kingsway Pharmaceuticals Inc. Therapeutic formulations for the treatment of cold and flu-like symptoms
KR20110079641A (en) 2008-09-09 2011-07-07 아스트라제네카 아베 Method for delivering a pharmaceutical composition to patient in need thereof
US7914828B2 (en) * 2008-10-17 2011-03-29 Levine Brian M Combination herbal product to benefit respiratory tract
US8518439B2 (en) * 2008-12-03 2013-08-27 Novartis Ag Liquid therapeutic composition
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
US8957095B2 (en) 2009-10-26 2015-02-17 Sephoris Pharmaceuticals, Llc Treatment of sunburn using analgesics and antihistamines
US8470375B1 (en) 2010-01-05 2013-06-25 Neos Therapeutics, Lp Method of formulating and designing liquid drug suspensions containing ion exchange resin particles
US8361519B2 (en) 2010-11-18 2013-01-29 Aadvantics Pharmaceuticals, Inc. Combination herbal product to benefit respiratory tract in people exposed to smoke
WO2013003622A1 (en) 2011-06-28 2013-01-03 Neos Therapeutics, Lp Dosage forms for oral administration and methods of treatment using the same
UA115139C2 (en) 2011-12-28 2017-09-25 Поузен Інк. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
MX2019003039A (en) 2016-09-26 2019-07-08 Procter & Gamble Extended relief dosage form.
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322427A (en) * 1981-04-16 1982-03-30 Bristol-Myers Company Analgetic compositions and methods of use
EP0097953A2 (en) * 1982-06-30 1984-01-11 E.I. Du Pont De Nemours And Company Synergistic compositions of nalbuphine and non-narcotic analgesic compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3936528A (en) * 1974-02-13 1976-02-03 Syntex Corporation Analgesic formulations having enhanced therapeutic activity
US4115589A (en) * 1977-05-17 1978-09-19 The Upjohn Company Compounds, compositions and method of use
US4279906A (en) * 1977-11-10 1981-07-21 Nasa Indomethacin-antihistamine combination for gastric ulceration control
US4374836A (en) * 1978-10-16 1983-02-22 Imperial Chemical Industries Ltd. Antisecretory heterocyclic derivatives, process for their manufacture and pharmaceutical compositions containing them
US4230717A (en) * 1978-12-29 1980-10-28 Lovelace Alan M Administrator Indomethacin-antihistamine combination for gastric ulceration control
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
CA1194799A (en) * 1981-12-10 1985-10-08 Eric L. Nelson Method and composition for reducing menstrual pain
IT1190663B (en) * 1982-01-21 1988-02-24 Ausonia Farma Srl COMPOUND WITH ANTI-INFLAMMATORY, ANALGESIC AND MUCOREGULATING ACTIVITY, PROCEDURE FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
US4447443A (en) * 1982-11-15 1984-05-08 Merck & Co., Inc. Anti-inflammatory/analgesic combination of α-fluoromethylhistidine and a selected non-steroidal anti-inflammatory drug (NSAID)
US4522826A (en) * 1984-02-08 1985-06-11 Richardson-Vicks Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322427A (en) * 1981-04-16 1982-03-30 Bristol-Myers Company Analgetic compositions and methods of use
EP0097953A2 (en) * 1982-06-30 1984-01-11 E.I. Du Pont De Nemours And Company Synergistic compositions of nalbuphine and non-narcotic analgesic compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 101, Nr. 23, 3 December 1984, (Columbus, Ohio, US) TRABER, DANUEL L.: "Ibuprofen and Diphenhydramine Reduce the Lung Lesion of Endotoxemia in Sheep", page 39, column 1, Abstract Nr. 204101x & J. TRAUMA, 1984, 24 (9), 835-40 see Abstract *
Unlisted Drugs, Volume 20, Nr. 11, November 1968, (Chatham, New Jersey, US) page 169n "Sinubid" (cited in the application) *
Unlisted Drugs, Volume 23, Nr. 3, March 1971, (Chatham, New Jersey, US) page 36, "Co-Tylenol" (cited in the application) *

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241615A1 (en) * 1986-04-15 1987-10-21 Warner-Lambert Company A pharmaceutical composition of phenindamine having enhanced release characteristics
EP0316434A1 (en) * 1987-06-08 1989-05-24 Abraham Sunshine Cough/cold mixtures comprising non-sedating antihistamine drugs.
EP0316434A4 (en) * 1987-06-08 1989-10-16 Abraham Sunshine Cough/cold mixtures comprising non-sedating antihistamine drugs.
EP0295212A2 (en) * 1987-06-10 1988-12-14 Warner-Lambert Company Process for preparing a pharmaceutical composition
EP0295212A3 (en) * 1987-06-10 1990-07-04 Warner-Lambert Company Process for preparing a pharmaceutical composition
EP0348683A1 (en) * 1988-06-01 1990-01-03 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions containing ibuprofen in combination with a piperidinoalkanol antihistamine
EP0384514A3 (en) * 1989-02-21 1991-04-03 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
EP0384514A2 (en) * 1989-02-21 1990-08-29 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
WO1991000088A1 (en) * 1989-06-23 1991-01-10 Boehringer Ingelheim France Novel use of 1-phenyl-2-aminoethanol derivatives as healing agents
US5173304A (en) * 1989-08-17 1992-12-22 Dolorgiet Beteiligungs Gmbh Agents for the treatment of severe pain and preparation of said agents
EP0413171A1 (en) * 1989-08-17 1991-02-20 Dolorgiet GmbH & Co. KG Strong analgesic composition and process for its preparation
WO1992004021A1 (en) * 1990-09-11 1992-03-19 Richardson Vicks Inc. Method for providing improved analgesic effect
WO1992004022A1 (en) * 1990-09-11 1992-03-19 Richardson Vicks Inc. Use of compositions containing 2-(6'-substituted-2'-naphthyl)-acetic acid derivatives for the treatment of respiratory disorders
WO1992015332A1 (en) * 1991-03-04 1992-09-17 Warner-Lambert Company Novel salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms
US5164398A (en) * 1991-04-01 1992-11-17 Merck & Co., Inc. Ibuprofen-antitussive combinations
EP0566393A1 (en) * 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
US5739165A (en) * 1992-04-17 1998-04-14 Takeda Chemical Industries, Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
WO1994014476A1 (en) * 1992-12-21 1994-07-07 The Procter & Gamble Company Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders
WO1994018970A1 (en) * 1993-02-18 1994-09-01 Warner-Lambert Company Cold/sinus preparation consisting of phenindamine tartarate with or without therapeutic agents
US5726180A (en) * 1993-06-30 1998-03-10 Takeda Chemical Industries, Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
US5629316A (en) * 1993-06-30 1997-05-13 Takeda Chemical Industries, Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
EP0631782A1 (en) * 1993-06-30 1995-01-04 Takeda Chemical Industries, Ltd. Stabilized solid pharmaceutical preparation containing dextromethorphan, phenylpropanolamine and caffeine
FR2708611A1 (en) * 1993-07-29 1995-02-10 Meram Lab Codeine salt of 2- (3-benzoylphenyl) propionic acid, process for obtaining same and pharmaceutical compositions containing it.
WO1995004058A1 (en) * 1993-07-29 1995-02-09 Les Laboratoires Meram 2-(3-benzoylphenyl)propionic acid codeine salt, preparation method therefor and pharmaceutical compositions containing said salt
WO1997004808A1 (en) * 1995-07-28 1997-02-13 The Procter & Gamble Company Compositions containing analgesics and antihistamines and methods for treating respiratory disorders
WO1997006801A1 (en) * 1995-08-18 1997-02-27 Parke Davis Composition containing mefenamic acid in association with codeine
FR2741264A1 (en) * 1995-11-16 1997-05-23 Parke Davis Compsn. contg. fenamic acid deriv. and codeine
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
WO1998048839A1 (en) * 1997-04-30 1998-11-05 Warner-Lambert Company Topical nasal antiinflammatory compositions
WO1999066919A1 (en) * 1998-06-19 1999-12-29 Mcneil-Ppc, Inc. Pharmaceutical composition containing a salt of acetaminophen and at least one other active ingredient
US7504409B2 (en) 2000-01-31 2009-03-17 Genaera Corporation Mucin synthesis inhibitors
EP1255544A1 (en) * 2000-01-31 2002-11-13 Magainin Pharmaceuticals, Inc. Mucin synthesis inhibitors
EP1255544A4 (en) * 2000-01-31 2005-02-02 Genaera Corp Mucin synthesis inhibitors
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
US7199153B2 (en) 2000-03-23 2007-04-03 Smithkline Beechman, P.L.C. Pharmaceutical composition comprising paracetamol and niflumic acid
WO2001070205A3 (en) * 2000-03-23 2002-04-04 Smithkline Beecham Plc Composition comprising paracetamol and niflumic acid
WO2001070205A2 (en) * 2000-03-23 2001-09-27 Smithkline Beecham P.L.C. Composition comprising paracetamol and niflumic acid
WO2001074341A3 (en) * 2000-03-30 2002-05-16 Schering Corp Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
SG96611A1 (en) * 2000-03-30 2003-06-16 Schering Corp Compositions and methods for treating allergic and inflammatory conditions with cough
WO2001074341A2 (en) * 2000-03-30 2001-10-11 Schering Corporation Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
WO2002096406A1 (en) * 2001-05-25 2002-12-05 Ssp Co., Ltd. Medicinal compositions
WO2003068203A1 (en) * 2002-01-30 2003-08-21 Zentiva, A.S. Use of a combination of a non-steroidal anti-inflammatory agent and guaifenesin for the treatment of acute pain
US8318709B2 (en) 2002-06-14 2012-11-27 Cipla Limited Combination of azelastine and mometasone for nasal administration
US9259428B2 (en) 2002-06-14 2016-02-16 Cipla Limited Combination of azelastine and fluticasone for nasal administration
US9901585B2 (en) 2002-06-14 2018-02-27 Cipla Limited Combination of azelastine and fluticasone for nasal administration
US8937057B2 (en) 2002-06-14 2015-01-20 Cipla Limited Combination of azelastine and mometasone for nasal administration
US8933060B2 (en) 2002-06-14 2015-01-13 Cipla Limited Combination of azelastine and ciclesonide for nasal administration
US8304405B2 (en) 2002-06-14 2012-11-06 Cipla Limited Combination of azelastine and ciclesonide for nasal administration
EP1572206A2 (en) * 2002-12-18 2005-09-14 Wyeth Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
US7863287B2 (en) 2002-12-18 2011-01-04 Wyeth Llc Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
AU2003301188B2 (en) * 2002-12-18 2009-07-02 Pf Consumer Healthcare 1 Llc Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
EP1572206A4 (en) * 2002-12-18 2007-07-18 Wyeth Corp Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
US6979689B2 (en) 2002-12-20 2005-12-27 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
WO2004058236A1 (en) * 2002-12-20 2004-07-15 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
DE102007000521A1 (en) 2007-10-18 2009-04-23 Renate Conrad cough preparation
EP2050435A1 (en) 2007-10-18 2009-04-22 Renate Conrad Cough mixture
GB2475359A (en) * 2009-11-11 2011-05-18 Biocopea Ltd A compound for use in treating a fulminant respiratory disorder
WO2016063057A1 (en) * 2014-10-21 2016-04-28 Reckitt Benckiser Llc Novel pharmaceutical formulation
US20170304296A1 (en) * 2014-10-21 2017-10-26 Reckitt Benckiser Llc Novel pharmaceutical formulation
WO2017062997A1 (en) * 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
WO2022119431A1 (en) * 2020-12-04 2022-06-09 Laboratorios Silanes S.A. De C.V. Pharmaceutical composition having an analgaesic and an antihistamine for treating respiratory diseases

Also Published As

Publication number Publication date
US4749722A (en) 1988-06-07
CA1258430A (en) 1989-08-15
ZA852485B (en) 1985-11-27
EP0180597B1 (en) 1992-03-04
US4920149A (en) 1990-04-24
US4552899A (en) 1985-11-12
US4749721A (en) 1988-06-07
US4619934A (en) 1986-10-28
US4749720A (en) 1988-06-07
ATE72989T1 (en) 1992-03-15
US4738966A (en) 1988-04-19
US4839354A (en) 1989-06-13
AU2029195A (en) 1995-08-03
DE3585495D1 (en) 1992-04-09
JPS61501913A (en) 1986-09-04
US4749723A (en) 1988-06-07
US4749711A (en) 1988-06-07
US4552899B1 (en) 1992-10-20
US4749697A (en) 1988-06-07
EP0180597A1 (en) 1986-05-14
AU589554B2 (en) 1989-10-19
JP2848556B2 (en) 1999-01-20
AU4120085A (en) 1985-11-01

Similar Documents

Publication Publication Date Title
AU589554B2 (en) Nsaids in cough/cold mixtures
US5025019A (en) Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
EP0311677B1 (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
US4985459A (en) Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
AU576825B2 (en) Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
EP0316434B2 (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
US4871733A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
PT1518555E (en) Analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
US20120064152A1 (en) Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same
US6900189B2 (en) Analgesic and glucosamine compositions
US4683243A (en) Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4755532A (en) Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
CA2476939A1 (en) Pharmaceutical combinations of cox-2 inhibitors and opiates
US4840962A (en) Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4585783A (en) Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4906625A (en) Analgesic and anti-inflammatory compositions comprising diphenhydramine and metyhods of using same
EP0555411A1 (en) Dextromethorphan antitussive compositions
AU738274B2 (en) Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
ZA200500064B (en) Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib.
WO1997048390A1 (en) Analgesics combining acetaminophen with meclizine

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU JP

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1985901895

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1985901895

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1985901895

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1985901895

Country of ref document: EP